238 related articles for article (PubMed ID: 29273385)
81. Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.
Kingma SD; Wagemans T; IJlst L; Wijburg FA; van Vlies N
J Inherit Metab Dis; 2014 Sep; 37(5):813-21. PubMed ID: 24699889
[TBL] [Abstract][Full Text] [Related]
82. Lipid composition of whole brain and cerebellum in Hurler syndrome (MPS IH) mice.
Heinecke KA; Peacock BN; Blazar BR; Tolar J; Seyfried TN
Neurochem Res; 2011 Sep; 36(9):1669-76. PubMed ID: 21253856
[TBL] [Abstract][Full Text] [Related]
83. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II.
Friso A; Tomanin R; Salvalaio M; Scarpa M
Br J Pharmacol; 2010 Mar; 159(5):1082-91. PubMed ID: 20136838
[TBL] [Abstract][Full Text] [Related]
84. Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry.
Zhang H; Young SP; Millington DS
Curr Protoc Hum Genet; 2013; Chapter 17():Unit 17.12. PubMed ID: 23315926
[TBL] [Abstract][Full Text] [Related]
85. Effects of enzyme replacement therapy started late in a murine model of mucopolysaccharidosis type I.
Pasqualim G; Baldo G; de Carvalho TG; Tavares AM; Giugliani R; Matte U
PLoS One; 2015; 10(2):e0117271. PubMed ID: 25646802
[TBL] [Abstract][Full Text] [Related]
86. Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells.
Pan C; Nelson MS; Reyes M; Koodie L; Brazil JJ; Stephenson EJ; Zhao RC; Peters C; Selleck SB; Stringer SE; Gupta P
Blood; 2005 Sep; 106(6):1956-64. PubMed ID: 15947088
[TBL] [Abstract][Full Text] [Related]
87. Endogenous, non-reducing end glycosaminoglycan biomarkers for the mucopolysaccharidoses: Accurate diagnosis and elimination of false positive newborn screening results.
Saville JT; Herbst ZM; Gelb MH; Fuller M
Mol Genet Metab; 2023 Nov; 140(3):107685. PubMed ID: 37604083
[TBL] [Abstract][Full Text] [Related]
88. Determination of urinary oligosaccharides by high-performance liquid chromatography/electrospray ionization-tandem mass spectrometry: Application to Hunter syndrome.
Nielsen TC; Rozek T; Hopwood JJ; Fuller M
Anal Biochem; 2010 Jul; 402(2):113-20. PubMed ID: 20382108
[TBL] [Abstract][Full Text] [Related]
89. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII.
Rowan DJ; Tomatsu S; Grubb JH; Montaño AM; Sly WS
J Inherit Metab Dis; 2013 Mar; 36(2):235-46. PubMed ID: 22971960
[TBL] [Abstract][Full Text] [Related]
90. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB
Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016
[TBL] [Abstract][Full Text] [Related]
91. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA.
Roberts AL; Thomas BJ; Wilkinson AS; Fletcher JM; Byers S
Pediatr Res; 2006 Sep; 60(3):309-14. PubMed ID: 16857766
[TBL] [Abstract][Full Text] [Related]
92. Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis.
Ou L; Przybilla MJ; Whitley CB
Mol Genet Metab; 2017; 120(1-2):101-110. PubMed ID: 27742266
[TBL] [Abstract][Full Text] [Related]
93. Updated Confirmatory Diagnosis for Mucopolysaccharidoses in Taiwanese Infants and the Application of Gene Variants.
Chuang CK; Tu YR; Lee CL; Lo YT; Chang YH; Liu MY; Liu HY; Chen HJ; Kao SM; Wang LY; Ho HJ; Lin HY; Lin SP
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077388
[TBL] [Abstract][Full Text] [Related]
94. Enzyme replacement therapy in feline mucopolysaccharidosis I.
Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
[TBL] [Abstract][Full Text] [Related]
95. Structure of heparan sulphate oligosaccharides and their degradation by exo-enzymes.
Linker A
Biochem J; 1979 Dec; 183(3):711-20. PubMed ID: 161508
[TBL] [Abstract][Full Text] [Related]
96. Left ventricular aneurysm in an adult patient with mucopolysaccharidosis type I: comment on pathogenesis of a novel complication.
Cabrera GH; Fernández I; Dominguez M; Clarke LA
Mol Genet Metab; 2012 Aug; 106(4):470-3. PubMed ID: 22732207
[TBL] [Abstract][Full Text] [Related]
97. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
[TBL] [Abstract][Full Text] [Related]
98. Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.
Downs-Kelly E; Jones MZ; Alroy J; Cavanagh KT; King B; Lucas RE; Baker JC; Kraemer SA; Hopwood JJ
J Mol Neurosci; 2000 Dec; 15(3):251-62. PubMed ID: 11303788
[TBL] [Abstract][Full Text] [Related]
99. The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening.
Taylor JL; Clinard K; Powell CM; Rehder C; Young SP; Bali D; Beckloff SE; Gehtland LM; Kemper AR; Lee S; Millington D; Patel HS; Shone SM; Woodell C; Zimmerman SJ; Bailey DB; Muenzer J
J Pediatr; 2019 Aug; 211():193-200.e2. PubMed ID: 31133280
[TBL] [Abstract][Full Text] [Related]
100. UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses.
Auray-Blais C; Lavoie P; Tomatsu S; Valayannopoulos V; Mitchell JJ; Raiman J; Beaudoin M; Maranda B; Clarke JT
Anal Chim Acta; 2016 Sep; 936():139-48. PubMed ID: 27566349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
